Trial Profile
Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Ascites; Liver cirrhosis
- Focus Therapeutic Use
- 24 Oct 2016 Primary endpoint has not been met. (Change from baseline in Hepatic venous pressure gradient (HVPG)), according to results published in the Hepatology.
- 24 Oct 2016 Results published in the Hepatology
- 19 Jan 2016 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.